title: Extended-Interval Aminoglycoside Use in Cystic Fibrosis Exacerbation in Children and Young Adults: A Prospective Quality Improvement Project.
abstract: This is a prospective quality improvement project for patients with cystic fibrosis who are 5 years of age and older who were admitted for intravenous antibiotic administration as part of treatment of cystic fibrosis exacerbation. The goal of this project was to compare the pharmacokinetics of once-daily versus thrice-daily aminoglycoside use when treating cystic fibrosis exacerbation in different age groups. Of the total of 119 patient encounters, 82.4% were started on once-daily dosing, and the remainder were started on thrice-daily dosing. Patients with pharmacokinetics allowing the continuation of once-daily dosing differed from patients who required a switch to thrice-daily dosing in terms of baseline forced expiratory volume in 1 second, forced expiratory flow from 25% to 75% of vital capacity, age, and body mass index (BMI) but were similar in BMI percentiles. The once-daily dosing group had higher mean 18-hour level, higher mean half-life, higher mean area under the curve, and lower mean elimination constant. This study showed that aminoglycoside clearance is higher in younger children.
authors.affiliation: University of Michigan, Ann Arbor, MI, USA.
authors.forename: Khalid H
authors.initials: KH
authors.lastname: Safi
authors.affiliation: University of Michigan, Ann Arbor, MI, USA.
authors.forename: Justina M
authors.initials: JM
authors.lastname: Damiani
authors.affiliation: University of Michigan, Ann Arbor, MI, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Sturza
authors.affiliation: University of Michigan, Ann Arbor, MI, USA.
authors.forename: Samya Z
authors.initials: SZ
authors.lastname: Nasr
keywords: bacterial resistance; once daily; pharmacokinetics; postantibiotic effect; thrice daily